Connect Biopharma Holdings Limited — Form 6-K Summary
Reporting period: Form 6-K filed November 22, 2021, covering information reported for November 2021. The filing announces a senior finance leadership change and does not provide operating or financial results.
Business Context
Connect Biopharma Holdings Limited is a foreign private issuer that files annual reports on Form 20-F. The company’s principal executive office is in Taicang, Jiangsu Province, China.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, research and development spending, or other financial metrics.
Material Changes
- Steven Chan was appointed Chief Financial Officer effective November 22, 2021.
- Mr. Chan also became the company’s Principal Accounting Officer.
- He succeeded Eric Hall, who had served as Interim Chief Financial Officer since August 2020.
- Mr. Chan previously served as Chief Financial Officer of Delphon Industries LLC and held finance and controller positions at Arcus Biosciences, MyoKardia, and Solta Medical.
Guidance, Outlook, Risks and Unusual Items
The filing provides no financial guidance, business outlook, risk updates, contingencies, or unusual financial items. The appointment information is incorporated by reference into the company’s Form S-8 registration statement, File No. 333-254524.
Investor Verification Points
- Verify the effective date and scope of Steven Chan’s CFO and Principal Accounting Officer responsibilities.
- Review subsequent filings for any updates concerning finance leadership, accounting controls, or reporting matters.
- Consult the company’s periodic reports for financial results, liquidity, capital requirements, and operating outlook, as none are included in this Form 6-K.